Medicare Fee Schedule Blanks On Next-Gen Sequencing

Labs and test makers say they are confused about what if anything Medicare contractors are paying for various molecular diagnostics including next-generation sequencing following CMS' recent release of codes and pricing for 2015. Meanwhile, industry groups are anxious that the agency has yet to issue a proposed rule to implement broader statutory changes to diagnostic price-setting.

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Policy & Regulation

More from Medtech Insight